Overview
Long COVID Labs (LCL) is a patient-led decentralized-science organization building an on-chain platform to find and deliver treatments for Long COVID — which it calls "the fastest growing chronic health condition in human history." It was incubated through the Bio Protocol launchpad as part of BIO Incubator Cohort 2, alongside Curetopia and Quantum Biology DAO.
LCL was founded by Rohan Dixit, a former neuroscientist at Stanford and the Harvard-MIT-MGH Martinos Center who contracted Long COVID after a mild 2020 infection and spent 2.5 years self-experimenting with therapies before co-founding the DAO. That origin shapes its defining feature: patients are treated as first-class stakeholders, not subjects — an inversion of a system where, in LCL's framing, "patients are excluded from decisions about their own care."
Where earlier BioDAOs such as VitaDAO organize around funding research and tokenizing its IP-NFTs, Long COVID Labs is structured as a therapeutics platform — its aim is to run trials and get treatments to patients directly, not only to fund upstream science.
The Long COVID problem
Long COVID affects roughly 100 million people globally and imposes an estimated $1 trillion per year in economic burden, per LCL's vision paper. The paper cites evidence that a single COVID infection is associated with an approximate 3–9 point IQ loss and may accelerate early-onset dementia — framing the condition as both a mass-scale and fast-growing chronic illness that traditional grant-and-trial pipelines are too slow to address.
LCL's thesis is that this mismatch — enormous, urgent patient demand versus a five-to-ten-year academic and regulatory timeline — is exactly the coordination failure a DAO can attack, by pooling patient data, community capital, and researcher effort in one incentive system.
The $COVID token and governance
Long COVID Labs is a decentralized autonomous organization wrapped in a Swiss non-profit and coordinated by the $COVID governance token. Of a 1 billion fixed supply, the vision paper allocates:
| Allocation | Share | Terms |
|---|---|---|
| Treasury reserves | 45% | unvested, DAO-controlled |
| Core team | 20% | 4-year vest, 1-year cliff |
| Community auction | 15% | 9 Jan 2025 sale, no vesting |
| Patients | 10% | for trial participation & data |
| Service provider (BIO) | 7% | unvested |
| Ecosystem incentives | 3% | — |
The token grants voting rights only — holders "do not receive any form of dividend or other revenue rights." Governance runs a three-stage process: idea proposals on social channels, roughly a week of discussion on Commonwealth, then a ~3-day binding vote on Snapshot. Notably, patients themselves hold a dedicated 10% of supply, giving the people who contribute clinical data a durable governance voice over research priorities.
The Adaptive Trial Engine
LCL's core technical bet is an Adaptive Trial Engine: instead of a handful of large, sequential trials, the platform is designed to run thousands of small adaptive clinical trials in parallel, using Bayesian inference to continuously update each treatment's success probability as patient data streams in, and machine learning to reallocate participants toward the arms that are working.
The roadmap phases this in: DAO establishment plus initial drug-repurposing studies (Q1 2025), the parallel adaptive-trial platform for antivirals and immune modulators (Q4 2025), scaling to dozens of trials and thousands of participants (Q3 2026), and permanent decentralized-research infrastructure beyond. LCL's first treatment candidate combines a long-acting monoclonal antibody with a viral-replication inhibitor, and its near-term strategy repurposes existing therapies such as Pemgarda and Paxlovid while contributors from Stanford, Mt. Sinai, and UCSF develop novel treatments.
Data, patients and IP
The model turns patient data contribution into governance stake: patients supply structured trial and real-world data, earn $COVID, and shape which treatments get prioritized — a concrete example of the research-data-ownership thesis that the people who generate biomedical data should share in its value.
On commercialization, LCL describes three IP pathways: licensing university-lab discoveries, licensing existing pharmaceutical IP for Long COVID re-purposing, and sponsoring internal research the DAO owns outright. In each case the stated intent is a "virtuous cycle" — profits from any resulting therapy flow back into the treasury and are reinvested into further research, rather than accruing solely to outside shareholders.
Place in the Bio Protocol ecosystem
Long COVID Labs sits in the Bio Protocol (bio.xyz) portfolio alongside VitaDAO (longevity), AthenaDAO (women's health), Cerebrum DAO (brain health), CryoDAO (cryopreservation) and Curetopia (rare disease). During its January 2025 auction, LCL distributed 1% of supply to $BIO holders who participated with ETH — the launchpad's standard curation-and-alignment mechanism.
Its distinguishing move within that set is the therapeutics-platform posture: most BioDAOs fund and tokenize research; LCL is trying to own the trial-to-treatment loop for a single, very large indication.
How Caper approaches this
Long COVID Labs answers a coordination failure with a token that pays the patients and scientists who do the work and hands them governance over what gets funded next. Caper generalizes that pattern into reusable primitives. A research collective launched as a caper funds treatments through typed proposals — a PAYOUT to pay a lab or trial site directly, or an INVEST to back an allied venture — while raising capital on a bonding curve rather than a one-off auction.
Crucially, a contributor's influence is their canonical vote weight — a function of both the governance tokens they hold and the votes they've earned — so the patients and researchers who show up accumulate real say over the treasury, not just a stake to sell. It's the same "reward the people who generate the value" logic LCL applies to Long COVID, expressed as protocol rules any research community can adopt.